Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100 240, on endocrine and renal functions in healthy volunteers

Journal of Hypertension

Volumn 17, Issue 3, 1999, Pages 427-437

  Rousso, Philippe ^a   Buclin, Thierry ^a   Nussberger, Jürg ^a   Décosterd, Laurent A ^a   La Roche, Salome D ^b,c   Brunner Ferber, Françoise ^b   Brunner, Hans R ^a   Biollaz, Jérôme ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b SANOFI   (France)

^c Covance CAPS ^*  (Switzerland)

Author keywords

Angiotensin converting enzyme; Atrial natriuretic peptide; Dual inhibitor; MDL 100 240; Neutral endopeptidase; Renal effects; Renin angiotensin aldosterone system

Indexed keywords

4 AMINOHIPPURIC ACID; 7 (2 ACETYLTHIO 3 PHENYLPROPIONAMIDO) 1,2,3,4,6,7,8,12B OCTAHYDRO 6 OXOPYRIDO[2,1 A][2]BENZAZEPINE 4 CARBOXYLIC ACID; ANGIOTENSIN; ATRIAL NATRIURETIC FACTOR; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FRUCTAN; LITHIUM; MEMBRANE METALLOENDOPEPTIDASE; SODIUM; URIC ACID;

4 AMINOHIPPURIC ACID CLEARANCE; ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ENDOCRINE FUNCTION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HEART RATE; HORMONE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; INULIN CLEARANCE; KIDNEY DISTAL TUBULE; KIDNEY FUNCTION; KIDNEY PLASMA FLOW; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE ABSORPTION; MALE; NORMAL HUMAN; POTASSIUM EXCRETION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SODIUM EXCRETION; SODIUM INTAKE; STANDING; SUPINE POSITION; URIC ACID URINE LEVEL; URINALYSIS; URINE VOLUME;

EID: 0033049453     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199917030-00017     Document Type: Article

References (53)

1. 1 Stephenson SL, Kenny AJ. The hydrolysis of alpha-human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase-24.11. Biochem J 1987; 243:183-187.
2. 2 Erdös EG, Skidgel RA. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J 1989; :145-151.
3. 3 Ura N, Carretero OA, Erdös EG. Role of renal endopeptidase 24.11 in kinin metabolism in vitro and in vivo. Kidney Int 1987; 32:507-513.
4. 4 Abassi ZA, Tate JE, Golomb E, Keiser HR. Role of neutral endopeptidase in the metabolism of endothelin. Hypertension 1992; 20:89-95.
5. 5 Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J 1993; 291:83-88.
6. 6 Sybertz EJ, Chiu PJS, Vemulapalli S, Pitts B, Foster CJ, Watkins RW, et al. SCH 39370, a neutral metalloendopeptidase inhibitor, potentiates biological responses to atrial natriuretic factor and lowers blood pressure in desoxycorticosterone acetate-sodium hypertensive rats. J Pharmacol Exp Ther 1989; 250:624-631.
7. 7 Sybertz Jr. EJ, Chiu JS, Watkins RW, Vemulapalli S. Neutral metallo-inhibition: a novel means of circulatory modulation. J Hypertens 1990; 8 (Suppl 7):S161-S167.
8. 8 Northridge DB, Alabaster CT, Connell JMC, Dilly SG, Lever AF, Jardine AG. Effects of UK 69578: a novel atriopeptidase inhibitor. Lancet 1989; II:591-593.
9. 9 Richards M, Espiner E, Frampton C, Ikram H, Yandle T, Sopwith M, et al. Inhibition of endopeptidase EC 24.11 in humans: renal and endocrine effects. Hypertension 1990; 16:269-276.
10. 10 Burnier M, Ganslmayer M, Perret F, Porchet M, Kosoglou T, Gould A, et al. Effects of SCH 34826, an orally active inhibitor of atrial natriuretic peptide degradation, in healthy volunteers. Clin Pharmacol Ther 1991; 50:181-191.
11. 11 Sagnella GA, Markandu ND, Buckley MG, Miller MA, Blackwood A, Singer DRJ, et al. Hormonal and renal responses to neutral endopeptidase inhibition in normal humans on a low and on a high sodium intake. Eur J Clin Invest 1995; 25:165-170.
12. 12 Lefrançois P, Clerc G, Duchier J, Kim C, Lecomte JM, Gros C, et al. Antihypertensive activity of sinorphan. Lancet 1990; 336:307-308.
13. 13 Richards AM, Crozier IG, Kosoglou T. Endopeptidase 24.11 inhibition by SCH 42495 in essential hypertension. Hypertension 1993; 22:119-126.
14. 14 Richards AM. The natriuretic peptides and hypertension. J Intern Med 1994; 235:543-560.
15. 15 Burnett JC Jr. The atrial peptide system in cardiac disease. Am J Hypertens 1988; 1 (Suppl):410S-420S.
16. 16 Margulies KB, Porrella MA, McKinley LJ, Burnett JC Jr. Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure. J Clin Invest 1991; 88:1636-1642.
17. 17 Trippodo NC, Fox M, Natarajan V, Panchal BC, Dorso CR, Assad MM. Combined inhibition of neutral endopeptidase and angiotensin converting enzyme in cardiomyopathic hamsters with compensated heart failure. J Pharmacol Exp Ther 1993; 267:108-116.
18. 18 Seymour AA, Asaad MM, Lanoce VM, Langenbacher KM, Fennell SA, Rogers WL. Systemic hemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dogs with pacing-induced heart failure. J Pharmacol Exp Ther 1993; 266:872-883.
19. 19 Seymour AA, Swerdel JN, Abboa-Offei B. Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin converting enzyme. J Cardiovasc Pharmacol 1991; 17:456-465.
20. 20 Pham I, Gonzalez W, El Amrani AIK, Fournié-Zaluski MC, Philippe M, Laboulandine I, et al. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension. J Pharmacol Exp Ther 1993; 265:1339-1347.
21. 21 Gonzalez Vera W, Fournié-Zaluski M-C, Pham I, Laboulandine J, Roques BP, Michel JB. Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats. J Pharmacol Exp Ther 1995; 272:343-351.
22. 22 French JF, Anderson BA, Downs TR, Dage RC. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase in rats with hypertension. J Cardiovasc Pharmacol 1995; 26:107-113.
23. 23 Stergiou GS, Hannah JA, Bevan EG, Lorimer AR, Carmichael HA, Hettiarachchi J, et al. Combined atriopeptidase inhibition and angiotensin converting enzyme inhibition in hypertensive patients. J Hypertens 1994; 12:1310-1311.
24. 24 Favrat B, Burnier M, Nussberger J, Lecomte JM, Brouard R, Waeber B, et al. Neutral endopeptidase versus angiotensin converting enzyme inhibition in esssential hypertension. J Hypertens 1995; 13:797-804.
25. 25 Flynn GA, Beight DW, Mehdi S, Koehl JR, Giroux EL, French JF. Application of a conformationally restricted Phe - Leu dipeptide mimetic to the design of a combined inhibitor of angiotensin I-converting enzyme and neutral endopeptidase 24.11. J Med Chem 1993; 36:2420-2423.
26. 26 French JF, Flynn GA, Giroux EL, Mehdi S, Anderson B, Beach DC, et al. Characterization of a dual inhibitor of angiotensin I-converting enzyme and neutral endopeptidase. J Pharmacol Exp Ther 1994; 268:180-186.
27. 27 Rousso P, Buclin T, Nussberger J, Brunner F, Brunner HR, Biollaz J. Effects of MDL 100 240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase, on the vasopressor response to exogenous angiotensin I and angiotensin II challenges in healthy volunteers. J Cardiovasc Pharmacol 1998; 31:408-417.
28. 28 Nussberger J, Brunner D, Keller I, Brunner HR. Measurement of converting enzyme activity by antibody-trapping of generated angiotensin II: comparison with two other methods. Am J Hypertens 1992; 5: 393-398.
29. 29 Nussberger J, Fasanella d'Amore T, Porchet M, Waeber B, Brunner DB, Brunner HR, et al. Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol 1987; 9:39-44.
30. 30 Nussberger J, Keller I, Waeber B, Brunner HR. Angiotensin II measurement with high-affinity monoclonal antibodies. J Hypertens 1988; 6 (Suppl 4):S424-S425.
31. 31 Nussberger J, Mooser V, Maridor G, Juillerat L, Waeber B, Brunner HR. Caffeine-induced diuresis and atrial natriuretic peptides. J Cardiovasc Pharmacol 1990; 15:685-691.
32. 32 Decosterd LA, Karagiannis A, Roulet JM, Belaz N, Appenzeller M, Buclin T, et al. High performance liquid chromatography of the renal blood flow marker p-aminohippuric acid (PAH) and its metabolite N-acetyl PAH improves PAH clearance measurements. J Chromatogr B 1997; 703:25-36.
33. 33 Séchaud R, Decosterd LA, Pechėre-Bertschi A, Biollaz J, Kesselring UW. Determination of the polyfructosan sinistrin in biological fluids by HPLC with electrochemical detection. J Pharm Biomed Anal 1996; 14:483-490.
34. 34 Magnin J-L, Decosterd LA, Centeno C, Burnier M, Diezi J, Biollaz J. Determination of trace lithium in biological fluids using graphite furnace atomic absorption spectrophotometry: variability of urine matrices circumvented by cation exchange solid phase extraction. Pharm Acta Helv 1996; 71:237-246.
35. 35 MacFadyen RJ, Elliott HL, Meredith PA, Reid JL. Haemodynamic and hormonal responses to oral enalapril in salt depleted normotensive man. Br J Clin Pharmacol 1993; 35:299-301.
36. 36 Düsing R, Moritz J, Glänzer K, Kramer HJ. Effect of angiotensin II and captopril on renal tubular function. Br J Clin Pharmacol 1985; 19:29-35.
37. 37 Bidivillo J, Bussien JP, Porchet M, Nussberger J, Waeber B, Brunner HR. Effect of prolonged angiotensin converting enzyme inhibition on ambulatory blood pressure of normotensive volunteers. Clin Exp Hypertens [A] 1987; 9:583-586.
38. 38 Fasanella d'Amore T, Bussien JP, Nussberger J, Waeber B, Tunni GA, Brunner HR, et al. Effects of single doses of the converting enzyme inhibitor cilazapril in normal volunteers. J Cardiovasc Pharmacol 1987; 9:26-31.
39. 39 Gardiner SM, Kemp PA, Brunner-Ferber F, Bennett T. Effects of the dual metallopeptidase inhibitor, MDL 100 240, on regional haemodynamic responses to vasoactive peptides in conscious rats. Br J Pharmacol 1997; 122:1687-1693.
40. 40 Abassi ZA, Golomb E, Bridenbaugh R, Keiser HR. Metabolism of endothelin-1 and big endothelin-1 by recombinant neutral endopeptidase EC.3.4.24.11. Br J Pharmacol 1993; 109:1024-1028.
41. 41 Sanchez RA, Marco E, Gilbert HB, Rafffaele P, Brito M, Gimenez M, et al. Natriuretic effect and changes in renal haemodynamics induced by enalapril in essential hypertension. Drugs 1985; 30:49-58.
42. 42 Motwani JG, Lang CC, Cramb G, Struthers AD. Natriuretic response to neutral endopeptidase inhibition is blunted by enalapril. Hypertension 1995; 25:637-642.
43. 43 Schmitt F, Martinez F, Ikeni A, Savoiu C, Natov S, Laborde K, et al. Acute renal effects of neutral endopeptidase inhibition in humans. Am J Physiol 1994; 267:F20-F27.
44. 44 Williams GH. Converting-enzyme inhibitors in the treatment of hypertension. N Engl J Med 1988; 319:1517-1525.
45. 45 McNabb WR, Noormohamed FH, Lant AF. The effects of enalapril on blood pressure and the kidney in normotensive subjects under altered sodium balance. J Hypertens 1986; 4:39-47.
46. 46 Richards AM, Wittert G, Espiner EA, Yandle TG, Frampton C, Ikram H. Prolonged inhibition of endopeptidase 24.11 in normal man: renal, endocrine and haemodynamic effects. J Hypertens 1991 ; 9:955-962.
47. 47 Harris PJ, Skinner SL. Intra-renal interactions between angiotensin II and atrial natriuretic factor. Kidney Int 1990; 38 (Suppl 30):S87-S91.
48. 48 Leary WP, Reyes AJ, van der Byl K. Effects of angiotensin-converting enzyme inhibitors on urinary excretions: interactions with diuretics. Am J Med 1992; 92 (Suppl 48):64S-68S.
49. 49 Leary WP, Reyes AJ, van der Byl KV, Acosta-Barrios TN. Effects of captopril, hydrochlorothiazide, and their combination on timed urinary excretions of water and solutes. J Cardiovasc Pharmacol 1985; 7 (Suppl 1):S56-S62.
50. 50 Good JM, Peters MP, Wilkins M, Jackson N, Oakley CM, Cleland JGF. Renal response to candoxatrilat in patients with heart failure. J Am Coll Cardiol 1995; 25:1273-1281.
51. 51 Biollaz J, Nussberger J, Porchet M, Brunner-Ferber F, Otterbein ES, Gomez H, et al. Four-hour infusions of synthetic atrial natriuretic peptide in normal volunteers. Hypertension 1986; 8:II96-II105.
52. 52 Cuneo RC, Espiner EA, Nicholls MG, Yandle TG, Joyce SL, Gilchrist NL. Renal, hemodynamic, and hormonal responses to atrial natriuretic peptide infusions in normal man, and effect of sodium intake. J Clin Endocrinol Metab 1986; 63:946-953.
53. 53 Labeeuw M, Pozet N, Zech PY, Hadj-Aissa A, Finaz de Villaine J, Laville M. Influence de l'administration aiguë de ramipril sur l'excrétion d'acide urique. Arch Mal Coeur Vaiss 1987; 80:870-874.